Overexpression and/or mutations of HER2 are observed in a variety of solid tumors, including approximately 15–20% of breast cancers [16], around 20% of gastric cancers [17], about 12% of bladder cancers [18], and roughly 25–30% of endometrial cancers [19]. This evidence concerns the gene ERBB2 and breast cancer.